PI3K/Akt signalling pathway and cancer.
暂无分享,去创建一个
Enrique Casado | Paloma Cejas | P. Cejas | E. Casado | M. González-Barón | Juan Angel Fresno Vara | Javier de Castro | Cristóbal Belda-Iniesta | Manuel González-Barón | C. Belda-Iniesta | J. de Castro | J. Á. Fresno Vara
[1] A. Schier,et al. Developmental Regulation of Expression and Activity of Multiple Forms of the Drosophila RAC Protein Kinase (*) , 1995, The Journal of Biological Chemistry.
[2] B. Hemmings,et al. Regulation of protein kinase B. , 1999, Journal of receptor and signal transduction research.
[3] F. Aoudjit,et al. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells , 2001, Oncogene.
[4] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[5] Linda N. Liu,et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. , 1999, Cancer research.
[6] S. Muthukkumar,et al. RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLS , 1995, Transplantation.
[7] S. Sebti,et al. Inhibitors of protein farnesyltransferase as novel anticancer agents. , 2002, Current Topics in Medicinal Chemistry.
[8] P. Dennis,et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.
[9] B. Evers,et al. Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] S. Nicosia,et al. Phosphatidylinositol 3-Kinase/Akt Pathway Regulates Tuberous Sclerosis Tumor Suppressor Complex by Phosphorylation of Tuberin* , 2002, The Journal of Biological Chemistry.
[11] R. K Srivastava,et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer , 2001, Oncogene.
[12] P. Edwards,et al. Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism , 1999, Oncogene.
[13] B. Evers,et al. Regulation of TRAIL Expression by the Phosphatidylinositol 3-Kinase/Akt/GSK-3 Pathway in Human Colon Cancer Cells* , 2002, The Journal of Biological Chemistry.
[14] M. Harada,et al. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] J. Testa,et al. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival , 2002, Oncogene.
[16] J. Um,et al. Potentiation of chemosensitivity in multidrug-resistant human leukemia CEM cells by inhibition of DNA-dependent protein kinase using wortmannin. , 2000, Leukemia research.
[17] C. Eng,et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. , 1999, Cancer research.
[18] G. Powis,et al. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. , 1995, Anticancer research.
[19] S. Hövelmann,et al. A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis , 2002, British Journal of Cancer.
[20] G. Mills,et al. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. , 2002, Cancer research.
[21] M. Hung,et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.
[22] E. Sausville,et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] J. Roth,et al. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. , 1991, Cancer research.
[24] M. Kris,et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] J. Blenis,et al. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. , 2002, Molecular cell.
[26] C. Davis,et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. , 2001, Critical reviews in oncology/hematology.
[27] M. Tsao,et al. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] M. Hung,et al. HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway* , 2000, The Journal of Biological Chemistry.
[29] J. D. Weber,et al. The ARF/p53 pathway. , 2000, Current opinion in genetics & development.
[30] J. Dodge,et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. , 1994, Cancer research.
[31] D. Fabbro,et al. Protein tyrosine kinase inhibitors: new treatment modalities? , 2002, Current opinion in pharmacology.
[32] M. Tsao,et al. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. , 2000, Cancer research.
[33] D. Lynch,et al. Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. , 2002, Seminars in oncology.
[34] J. Sarkaria,et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. , 1998, Cancer research.
[35] B. Hemmings,et al. Molecular cloning of a second form of rac protein kinase. , 1991, Cell regulation.
[36] Jiayuh Lin,et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. , 2000, Anticancer research.
[37] David J. Kwiatkowski,et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[38] P. Houghton,et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. , 1998, Molecular pharmacology.
[39] J. Woodgett,et al. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[40] S. Semba,et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma , 2002, Cancer.
[41] G. Mills,et al. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells , 1999, Oncogene.
[42] Chen-Yang Shen,et al. PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.
[43] B. Geoerger,et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. , 2001, Cancer research.
[44] T. Cotter,et al. Molecular signals in anti-apoptotic survival pathways , 2001, Leukemia.
[45] M. Hambek,et al. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. , 2001, Cancer research.
[46] R H Wheeler,et al. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] G. Evan,et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB , 1997, Nature.
[48] S. Staal. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[49] A. Wakeling. Epidermal growth factor receptor tyrosine kinase inhibitors. , 2002, Current opinion in pharmacology.
[50] Alfonso Bellacosa,et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer , 2002, Nature Medicine.
[51] J. Cheng,et al. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas , 1998, Molecular carcinogenesis.
[52] Hemant K Roy,et al. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. , 2002, Carcinogenesis.
[53] Joe W. Gray,et al. PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.
[54] K. Rosenzweig,et al. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. , 1997, Clinical Cancer Research.
[55] G. Mills,et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. , 1995, Cancer research.
[56] J. Woodgett,et al. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. , 1991, European journal of biochemistry.
[57] Carlos L. Arteaga,et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.
[58] Sheo B. Singh,et al. Current progress on farnesyl protein transferase inhibitors. , 2002, Current opinion in drug discovery & development.
[59] G. Mills,et al. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[60] S. Dedhar,et al. Regulation of Protein Kinase B/Akt-Serine 473 Phosphorylation by Integrin-linked Kinase , 2001, The Journal of Biological Chemistry.
[61] P. Nowell,et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[62] R. Herbst. ZD1839: targeting the epidermal growth factor receptor in cancer therapy , 2002, Expert opinion on investigational drugs.
[63] G. Mills,et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells , 2003, Oncogene.
[64] L. Pustilnik,et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. , 1999, The Journal of pharmacology and experimental therapeutics.
[65] T. Seufferlein,et al. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. , 1999, Cancer research.
[66] T. Hunter,et al. Signaling—2000 and Beyond , 2000, Cell.
[67] R. Parsons,et al. PTEN: life as a tumor suppressor. , 2001, Experimental cell research.
[68] B. Monia,et al. Antisense Oligonucleotides Demonstrate a Dominant Role of c-Ki-RAS Proteins in Regulating the Proliferation of Diploid Human Fibroblasts* , 1996, The Journal of Biological Chemistry.
[69] Yosef Yarden,et al. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.
[70] J. Douros,et al. New antitumor substances of natural origin. , 1981, Cancer treatment reviews.
[71] Tian Xu,et al. Akt regulates growth by directly phosphorylating Tsc2 , 2002, Nature Cell Biology.
[72] T. Pawson,et al. Protein-protein interactions define specificity in signal transduction. , 2000, Genes & development.
[73] M. Roussel,et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.
[74] J. Slingerland,et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.
[75] G. Paine-Murrieta,et al. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase , 1999, Cancer Chemotherapy and Pharmacology.
[76] R. K Srivastava,et al. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. , 2002, Cancer research.
[77] Y. Whang,et al. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway , 2002, Oncogene.
[78] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[79] P. Dennis,et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.
[80] J. Testa,et al. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. , 1991, Science.
[81] Alfonso Bellacosa,et al. AKT plays a central role in tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[82] R. Weber,et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[83] S. Sehgal,et al. Activity of rapamycin (AY-22,989) against transplanted tumors. , 1984, The Journal of antibiotics.
[84] J. Testa,et al. Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization , 2000, Cytogenetic and Genome Research.
[85] J. Massagué. TGF-beta signal transduction. , 1998, Annual review of biochemistry.
[86] P. Cohen,et al. Mechanism of activation of protein kinase B by insulin and IGF‐1. , 1996, The EMBO journal.
[87] Michael A Davies,et al. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells , 2000, Oncogene.
[88] T. Seufferlein,et al. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. , 1996, Cancer research.
[89] B. Hemmings,et al. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[90] J. Cheng,et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[91] E K Rowinsky,et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] J. Cheng,et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.
[93] S. Crooke. Potential roles of antisense technology in cancer chemotherapy , 2000, Oncogene.
[94] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[95] K. M. Nicholson,et al. The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.
[96] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[97] Roy S Herbst,et al. Monoclonal antibodies to target epidermal growth factor receptor–positive tumors , 2002, Cancer.
[98] K. Inoki,et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.
[99] F. Casagrande,et al. G1 phase arrest by the phosphatidylinositol 3‐kinase inhibitor LY 294002 is correlated to up‐regulation of p27Kip1 and inhibition of G1 CDKs in choroidal melanoma cells , 1998, FEBS letters.
[100] E. Rowinsky,et al. The ErbB receptor family: a therapeutic target for cancer. , 2002, Trends in molecular medicine.
[101] P. Warne,et al. Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras , 1997, Cell.